Ensign Peak Advisors’s Standard BioTools LAB Stock Holding History

Ensign Peak Advisors’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-80	Closed	–	–	2184
2022 Q1	$0	Hold	80	–	–	﹤0.01%	2233
2021 Q4	$0	Buy	+80	New	+$375	﹤0.01%	2218

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ensign Peak Advisors's LAB Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Standard BioTools (LAB) in Q2 2022, closing a stake of 80 shares.

Ensign Peak Advisors first reported a position in LAB in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 86 funds tracked by Wall St. Rank hold LAB as of Q2 2022.

Ensign Peak Advisors reported no remaining Standard BioTools position as of Q2 2022 after selling out during the quarter.
Ensign Peak Advisors sold 80 Standard BioTools shares in Q2 2022.
Ensign Peak Advisors first reported a position in Standard BioTools in Q4 2021 and held it in 2 quarters.
Ensign Peak Advisors's Standard BioTools position peaked at $0 in Q1 2022.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.